Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Eribulin + ZW25 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Eribulin | Halaven | Antimicrotubule Agent 14 | ||
ZW25 | ZW-25|Zanidatamab | HER2 (ERBB2) Antibody 76 | Zanidatamab (ZW25) is a bispecific antibody targeting ERBB2 (HER2), which induces anti-tumor immune response against Erbb2 (Her2)-expressing tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P, PMID: 32054397). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06435429 | Phase III | Capecitabine + ZW25 Eribulin + ZW25 Trastuzumab + Vinorelbine Gemcitabine + ZW25 Capecitabine + Trastuzumab Gemcitabine + Trastuzumab Vinorelbine + ZW25 Eribulin + Trastuzumab | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Recruiting | USA | 0 |